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INTRODUCTION
Asthma is one of the most common chronic illnesses in
children, and obesity is another important public health prob-
lem that can affect children (1, 2). Recently the prevalence of
both asthma and obesity have increased substantially in many
countries, leading to speculation that obese people might be
at an increased risk of developing asthma (3, 4). Although a
large number of studies have been performed, the possibility
that obesity might increase the risk of asthma development
remains controversial (5). Nevertheless, potential mechanisms
have been suggested that obesity-related changes in lung vol-
umes, systemic inflammation, and other adipocyte-derived
factors such as leptin, adiponectin, resistin, and visfatin, as
well as cytokines and chemokines that might alter smooth
muscle function in such a way as to promote airway narrow-
ing (2, 6).
Asthma is recognized as a chronic inflammatory disease
in the airways (7), and the obese state is characterized by low-
grade systemic inflammation, as indicated by increased levels
of the inflammatory markers c-reactive protein (CRP) and
IL-6 in the circulation of obese subjects (6). The effects of
increased body mass index (BMI) on asthma may be medi-
ated by upregulation of inflammatory mechanisms in the air-
way epithelium (8). The current view of adipose tissue is that
of an active secretory organ, sending out and responding to
signals that modulate appetite, energy expenditure, insulin
sensitivity, endocrine and reproductive systems, bone meta-
bolism, and inflammation and immunity (6). The serum con-
centrations of many adipokines could impact airway function,
which might lead to asthma in both human and murine sub-
jects with obesity (9). A recent study showed that leptin, an
adipokine, might play a role in atopic asthma in children (8).
Retinol-binding protein (RBP) 4 is highly expressed in iso-
lated mature human adipocytes and secreted by differentiat-
ing human adipocytes (10). Previous studies have reported
significant associations between RBP4 levels and BMI (11,
12). In contrast, other studies have not found a link between
RBP4 levels and BMI (13, 14). Recent reports showed that
RBP4 correlated with inflammatory factors such as CRP and
IL-6 (15), and RBP4 mRNA had a strong positive correla-
tion with markers of adipose inflammation (monocyte che-
moattractant protein-1 and CD68) (16). Several studies have
been reported on the relationship between RBP4 and obesi-
ty, adipose inflammation but, there has been no reports show-
ing association between RBP4 and childhood asthma. 
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Clinical Implications of Serum Retinol-Binding Protein 4 in 
Asthmatic Children
Recently the prevalence of both asthma and obesity have increased substantially
in many countries. The aim of this study was to evaluate the role of retinol-binding
protein (RBP) 4 in childhood asthma and its association with atopy markers, pul-
monary function, and bronchial hyperresponsiveness in relation to obesity. We stud-
ied 160 children between the ages 6 to 10 yr, including 122 asthmatics and 38 con-
trols. The body mass index, pulmonary function tests, and methacholine challenge
tests were measured on the same day. Total eosinophil count, serum total IgE, serum
eosinophil cationic protein, and serum RBP4 were measured in all subjects. There
was no difference in serum RBP4 levels between the asthmatics and the control
group. In all subjects or subgroups, serum RBP4 was not associated with total eosi-
nophil count, serum total IgE, serum eosinophil cationic protein, or PC20. There was
no relationship between serum RBP4 and pulmonary function in female asthmat-
ics. Forced expiratory volume in 1 second/forced vital capacity (FVC) and forced
expiratory flow between 25% and 75% of FVC contributed to serum RBP4 in male
asthmatics. Our findings show an association between RBP4 and pulmonary func-
tion in prepubertal male asthmatics. This relationship may indirectly affect the high
prevalence of childhood asthma in males.
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We evaluated the role of RBP4 in childhood asthma and
its association with atopy markers, pulmonary function, and
bronchial hyperresponsiveness.
MATERIALS AND METHODS
Subjects
One hundred sixty prepubertal subjects, aged from 6 to
10 yr, were recruited from Severance Hospital, Yonsei Uni-
versity College of Medicine. Asthma was defined as recurrent
wheezing or coughing episodes in the absence of common
cold in the preceding 12 months. Additionally a physician’s
diagnosis of bronchial hyperresponsiveness upon methacholine
challenge (PC20≤16 mg/mL) and at least 12% reversibility
of forced expiratory volume in 1 second (FEV1) after inhaling
a β2 agonist, as per criteria of the American Thoracic Society
(ATS), were required (17). All participants were enrolled before
administering oral or inhaled corticosteroids. Children with
history of asthma attacks requiring systemic corticosteroids
within the preceding 6 months were excluded. The control
participants were age-matched healthy children who visited
the hospital for a general health work-up or vaccination and
had no history of wheezing, recurrent chronic disease, infec-
tion during the preceding two weeks, or hypersensitivity to
methacholine. 
Height and weight were measured in light clothing with-
out shoes to calculate BMI in kg/m2. Obesity and overweight
classification were defined by BMI for age and sex based on
an international survey (18). Absolute BMI values were then
converted to previously established BMI percentiles of Korean
children for data analysis (19). The 85th and 95th percentiles
of BMI for age and sex were used as cut off values to identi-
fy normal weight, overweight and obesity. Informed written
consent was obtained from all participants before inclusion
in the study. The study was approved by the Severance Hos-
pital Institutional Review Board beforehand.
Spirometry and methacholine challenge test
Lung function was measured by spirometry (Vmax encore;
VIASYS Healthcare Inc., Conshohocken, PA, U.S.A.) accord-
ing to ATS standards (17). Bronchial hyperresponsiveness
was assessed in all participants by the methacholine challenge
test. Children were eligible if they could perform reproducible
spirometry and had an FEV1 of at least 70% of the predicted
value (20). In short, after saline inhalation, doses of metha-
choline (0.075, 0.15, 0.31, 0.62, 1.25, 2.5, 5, 10, and 25
mg/mL) were delivered for 0.6 sec through a DeVilbiss 646
nebulizer using a Rosenthal-French dosimeter (Ferraris, Hert-
ford, England) until either FEV1 decreased by 20% or more,
or the highest dose administered. FEV1 was measured 60 to
90 sec after each inhalation. The methacholine concentration
inducing a 20% decrease in FEV1 (PC20) was recorded. The
challenge test was considered positive if the PC20 was 16 mg/
mL or less. Anti-inflammatory preparations and bronchodila-
tors were withheld for 24 hr before the test.
Measurement of blood eosinophils, serum total IgE, serum
eosinophil cationic protein (ECP) and serum RBP4 levels
The NE-8000 system (Sysmex, Kobe, Japan) was used to
count eosinophils automatically in peripheral blood. Serum
total IgE and ECP were measured by the CAP radioallergosor-
bent technique (UniCAP; Pharmacia and Upjohn, Uppsala,
Sweden). Blood samples to measure serum RBP4 levels were
obtained between 6 a.m. and 9 a.m. after an overnight fast.
After clotting at 4℃, the serum was separated by centrifu-
gation at 1,300 g for 10 min and stored at -70℃ until the
assays. Serum RBP4 concentrations were measured with a
human RBP4 Competitive ELISA Kit (AdipoGen, Seoul,
Korea) according to the manufacturer’s instructions. The min-
imum RBP4 detection limit was 1 ng/mL and all assays were
performed in duplicate for each sample, with the mean val-
ues reported here. 
Statistical analysis
Descriptive statistics were calculated as the mean±SD or
as median (interquartile range) for continuous variables. Com-
parisons between groups were made using a Student’s t-test,
Mann-Whitney U test or chi-square test. Simple linear regres-
sion analysis was performed to assess the age, BMI, FEV1,
FEV1/forced vital capacity (FVC), forced expiratory flow bet-
ween 25% and 75% of FVC (FEF25-75%), PC20, eosinophil count,
serum total IgE and ECP on RBP4 levels. A P value less than
0.05 was considered statistically significant. All analyses were
performed on the Statistical Package for the Social Sciences
software (version 13.0, SPSS Inc, Chicago, IL, U.S.A.). 
RESULTS
The study included 122 patients with asthma and 38 con-
trols. The participants consisted of 102 boys (63.8%) and
58 girls (36.2%) (mean age, 8.6±1.2 yr). The mean values
for age and BMI percentile were not different between the
asthmatics and healthy children. Boys were more predomi-
nant in the asthmatic group. Eosinophil count, serum total
IgE and ECP were statistically higher in the asthmatics than
the control subjects. FEF25-75% was significantly lower in the
asthmatics than the control subjects (Table 1). In asthmatics,
there was no gender difference in asthma severity (P=0.256)
(Table 2).
The mean RBP4 concentration, shown in Fig. 1, was not
significantly different between the asthmatics and control
subjects (mean±SD, 256.91±93.37 μg/mL vs. 264.20±
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151.79 μg/mL, P=NS). 
Simple linear regression analysis was performed with RBP4
as the dependent variable and age, BMI percentile, eosinophil
count, serum total IgE, ECP, FEV1, FEV1/FVC, FEF25-75% and
PC20 as the independent variables for asthmatics divided by
sex (Table 3). The results indicate that FEV1/FVC and FEF25-75%
contribute significantly to serum RBP4 level in boys with
asthma. No other parameters were shown to contribute to
RBP4. No variables significantly contributed to RBP4 in
girls with asthma. In normal weight, overweight, and obe-
sity group, no variables were correlated to RBP4 in both sexes
and between the asthmatics and the control subjects (data
not shown). According to asthma severity, serum total IgE
and FEF25-75% contribute to serum RBP4 only in mild asth-
ma group (data not shown). In male asthmatics, serum total
IgE, FEV1, and FEF25-75% also contribute significantly to serum
RBP4 in mild group (data not shown). No variables were
*mean±SD; �median (interquartile range).
BMI, body mass index; ECP, eosinophil cationic protein; FEV1, forced
expiratory volume in 1 second, FVC, forced vital capacity; FEF25-75%, forced
expiratory flow between 25% and 75% of forced vital capacity.
Characteristics Asthma (n=122) Control (n=38) P value
Age (yr)* 8.6±1.2 8.4±0.9 0.115
Male/Female (n) 84/38 18/20
BMI percentile* 64.66±30.33 63.89±30.43 0.893
Normal weight/ 78/22/22 23/6/9
overweight/ (63.9/18.0/18.0) (60.5/15.8/23.7)
obesity (%)
Eosinophil count (/μL)� 305.00 150.00 0.011
(190.00-700.00) (70.00-232.50)
Serum total IgE (U/mL)� 206.50 45.80 0.000
(79.73-581.50) (31.23-87.50)
Serum ECP (μg/L)� 14.60 7.39 0.000
(5.91-36.00) (3.89-11.48)
FEV1/FVC (% predicted)* 102.91±8.25 105.28±4.76 0.099
Baseline FEV1 83.46±14.80 91.66±12.85 0.058
(% predicted)*
FEF25-75% (% predicted)* 79.70±23.55 90.81±26.34 0.024
Table 1. Selected characteristics to asthma status of participants
*Severity of asthma was classified according to GINA guidelines; �Mild
asthma group includes mild intermittent and mild persistent asthma
group.
Severity of asthma*
Asthmatics (n=122)
Male (n=84) Female (n=38)
Mild asthma� 34 (40.5%) 16 (42.1%)
Moderate asthma 28 (33.3%) 18 (47.4%)
Severe asthma 22 (26.2%) 4 (10.5%)
Table 2. Details of asthmatics
Fig. 1. Serum RBP4 levels do not show any difference between the
asthmatics and the controls in all, male and female participants
(P>0.05). Data represent median values.
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In all analyses, the dependent variable was RBP4. All analyses are adjusted for age.
B, unstandardized regression coefficient; SE, standard error; Beta, standardized; regression coefficient; BMI, body mass index; TEC, total eosinophil
count; ECP, eosinophil cationic proteinl; FEV1, forced exporatory volume in 1 second, FVC, forced vital capacity; FEF25-75%, forced expiratory flow
between 25% and 75% of forced vital capacity. 
Asthmatics (n=122)
B
Male (n=84)
Unstandardized coefficients
Variables Standardized 
coefficients
SE Beta
P value
B
Female (n=38)
Unstandardized coefficients Standardized 
coefficients
SE Beta
P value
BMI 0.021 0.028 0.084 0.447 0.029 0.076 0.071 0.705
TEC 0.000 0.000 0.125 0.257 0.000 0.001 0.078 0.676
IgE 0.000 0.000 0.176 0.108 0.001 0.000 0.346 0.056
PC20 -0.037 0.020 -0.199 0.070 0.016 0.023 0.128 0.491
ECP -0.003 0.003 -0.100 0.378 0.008 0.009 0.160 0.406
FEV1 -0.010 0.006 -0.192 0.103 0.004 0.019 0.042 0.839
FVC -0.006 0.007 -0.106 0.377 0.009 0.019 0.099 0.636
FEV1/FVC -0.025 0.011 -0.286 0.020 0.021 0.042 0.108 0.623
FEF25-75% -0.012 0.004 -0.345 0.003 0.006 0.011 0.117 0.571
Table 3. Simple linear regression analysis between RBP4 and variables in asthmatics
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associated with serum RBP4 in moderate and severe group
both in all and male asthmatics (data not shown).
DISCUSSION
The aim of this study was to investigate serum RBP4 levels
and its relationship between the parameters of atopy, pulmo-
nary function, and bronchial hyperresponsiveness. There were
no differences in mean serum RBP4 concentrations between
the asthmatics and the control subjects. There was also no sig-
nificant correlation between serum RBP4 and BMI for both
the asthmatics and control group. FEV1/FVC and FEF25-75%
contributed to serum RBP4 levels in male asthmatics. 
There are several proposed mechanisms by which obesity
can affect airway function (21). A recent review touched on
the mechanical, immunological, hormonal and inflammato-
ry effects of obesity that may play a role in the development
and persistence of asthma (21, 22). Although a large num-
ber of cross-sectional, case-control, prospective and weight
loss studies have been performed, the possibility that obesi-
ty might increase the risk of asthma development still remains
controversial (3, 21). Our findings suggest that there is no
direct association between BMI and asthma. Although a small
study sample and a relatively small obese group may have
affected the results, the proportion of obese people in our
study is similar to the proportion of obese people in the gen-
eral Korean population. Both the low proportion of obesity
and the rarity of severe obesity in Korea may also have affect-
ed the results. The fact that the subjects were prepubertal
(younger than 10 yr) may also have influenced the results by
excluding the effects of sex hormones. Although the possi-
bility that obesity might increase the risk of asthma remains
controversial, their correlation is still a matter of concern. It
is well documented that obesity is an inflammatory state that
leads to increased levels of hormones such as leptin, cytokines
such as interleukin-6 and tumor necrosis factor-α, chemokines
and other inflammatory mediators that could potentially influ-
ence airway smooth muscle (6). RBP4 is a newly discovered
fat-derived peptide that modulates glucose metabolism and
consequently induces insulin resistance (23). A recent report
suggests that RBP4 is a central mediator of obesity-induced
insulin resistance in mice and humans (24). Mean serum RBP4
levels were elevated in both nondiabetic and diabetic obese
subjects, and serum RBP4 levels were positively correlated
with BMI (25). Previous studies have shown that RBP4 lev-
els are elevated in obese patients (12, 24, 25). On the other
hand, another report showed no association between plasma
RBP4 levels and BMI (13). Our results show that serum RBP4
is not related to BMI. RBP4 level was not different between
the asthmatics and normal control groups, and there were no
differences in BMI between the asthmatics and controls in
our study. The relatively narrow BMI distribution of our study
subjects might explain the lack of a relationship. 
Simple linear regression analysis revealed that both FEV1/
FVC and FEF25-75% are predictive factors of RBP4 for male
asthmatics in our study. The FEV1 to FVC ratio is a useful
assessment of airflow limitation (26). Recently, FEV1/FVC
was reported to be a predictive factor for basement membrane
thickness, which is a known early airway remodeling marker
(27). Among the respiratory indices derived from the forced
vital capacity maneuver, maximal midexpiratory flow rate
(MMEF) namely FEF25-75%, which measures the average flow
of gas through the middle lung volumes, was originally con-
sidered a more sensitive and earlier marker of obstruction in
the small airways than FEV1 (28, 29). Our findings show that
these two parameters contribute to serum RBP4 levels. The
relationship between serum RBP4 and pulmonary function
might be indirectly associated with lung inflammation, changes
in small airways, and airflow obstruction, all part of asthma
pathogenesis. It is known that asthma is more prevalent in
boys younger than 10 yr or the mid-teens, at which point
asthma is more prevalent in girls until sexual maturity (30).
A current study shows that high serum leptin levels in asth-
matic boys may partly explain the higher prevalence of child-
hood asthma in males (8). Our results support this pheno-
menon. No explanation for the phenomenon has been given.
The often hypothesized role of sexual hormones still remains
to be demonstrated (30). 
Our research establishes the first causal relationship bet-
ween serum RBP4 and asthma. We excluded the effects of
sex hormones by recruiting prepubertal children as study
subjects. The small number of participants and the relative-
ly small obese group are limitations of this study. Relatively
small number of female asthmatics may also have affected
the results.
In conclusion, our findings suggest an association between
RBP4 and pulmonary function in prepubertal male asthmat-
ics. This relationship may indirectly affect the high preva-
lence of childhood asthma in males.
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